BioSpace · 新闻稿·· 10 天前AI 评分60
[交易线索][线索待核实]ORIC与Cancer Research UK达成协议，推进潜在first-in-class CIP2A靶向疗法进入临床开发
ORIC® Pharmaceuticals Announces Agreement with Cancer Research UK to Advance a Potential First-in-Class CIP2A-Targeted Therapy Into Clinical Development
AI 导读
ORIC Pharmaceuticals与Cancer Research UK达成协议，由Cancer Research UK的药物开发中心全额资助、申办、设计并执行ORIC-259的CTA-enabling研究及早期临床开发。 公司：ORIC Pharmaceuticals 相关资产：ORIC-259 适应症：HRD相关癌症 阶段：临床前，即将进入1/2期临床 融资性质：不适用 来源：BioSpace · 新闻稿（https://www.biospace.com/press-releases/oric-pharmaceuticals-announces-agreement-with-cancer-research-uk-to-advance-a-potential-first-in-class-cip2a-targeted-therapy-into-clinical-development）
来源：BioSpace · 新闻稿 · biospace.com
正在验证登录状态…